Cargando…

Population Pharmacokinetic Analysis of the BTK Inhibitor Zanubrutinib in Healthy Volunteers and Patients With B‐Cell Malignancies

Zanubrutinib is a potent, second‐generation Bruton’s tyrosine kinase inhibitor that is currently being investigated in patients with B‐cell malignancies and recently received accelerated approval in the United States for treatment of relapsed/refractory mantle cell lymphoma. The objective of this an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ou, Ying C., Liu, Lucy, Tariq, Bilal, Wang, Kun, Jindal, Ashutosh, Tang, Zhiyu, Gao, Yuying, Sahasranaman, Srikumar
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7993273/ https://www.ncbi.nlm.nih.gov/pubmed/33306268 http://dx.doi.org/10.1111/cts.12948

Ejemplares similares

Effect of rifampin and itraconazole on the pharmacokinetics of zanubrutinib (a Bruton's tyrosine kinase inhibitor) in Asian and non-Asian healthy subjects
por: Mu, Song, et al.
Publicado: (2019)

Comprehensive PBPK model to predict drug interaction potential of Zanubrutinib as a victim or perpetrator
por: Wang, Kun, et al.
Publicado: (2021)

In vitro investigations into the roles of CYP450 enzymes and drug transporters in the drug interactions of zanubrutinib, a covalent Bruton's tyrosine kinase inhibitor
por: Zhang, Heather, et al.
Publicado: (2021)

Coming of Age for BTK Inhibitor Therapy: A Review of Zanubrutinib in Waldenström Macroglobulinemia
por: Muñoz, Javier, et al.
Publicado: (2022)

Molecular associations of response to the new-generation BTK inhibitor zanubrutinib in marginal zone lymphoma
por: Tatarczuch, Maciej, et al.
Publicado: (2023)

Evaluation of drug interaction potential of zanubrutinib with cocktail probes representative of CYP3A4, CYP2C9, CYP2C19, P‐gp and BCRP
por: Ou, Ying C., et al.
Publicado: (2021)

No QTc Prolongation With Zanubrutinib: Results of Concentration‐QTc Analysis From a Thorough QT Study in Healthy Subjects
por: Mu, Song, et al.
Publicado: (2020)

Safety, Tolerability, Pharmacokinetics, Target Occupancy, and Concentration‐QT Analysis of the Novel BTK Inhibitor Evobrutinib in Healthy Volunteers
por: Becker, Andreas, et al.
Publicado: (2019)

Model‐based population pharmacokinetic analysis of tislelizumab in patients with advanced tumors
por: Budha, Nageshwar, et al.
Publicado: (2022)

BTK gatekeeper residue variation combined with cysteine 481 substitution causes super-resistance to irreversible inhibitors acalabrutinib, ibrutinib and zanubrutinib
por: Estupiñán, H. Yesid, et al.
Publicado: (2021)

Enrichment of BTK Leu528Trp mutations in patients with CLL on zanubrutinib: potential for pirtobrutinib cross-resistance
por: Blombery, Piers, et al.
Publicado: (2022)

PB1926: EFFICACY AND SAFETY OF ONCE DAILY (QD) VS TWICE DAILY (BID) ZANUBRUTINIB FOR PATIENTS WITH VARIOUS B-CELL MALIGNANCIES: A COMPARATIVE SUMMARY OF CLINICAL DATA AND EXPOSURE-RESPONSE ANALYSES
por: Tam, Constantine, et al.
Publicado: (2023)

Treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma with the BTK inhibitor zanubrutinib: phase 2, single-arm, multicenter study
por: Xu, Wei, et al.
Publicado: (2020)

Safety, pharmacokinetics, and pharmacodynamics of BMS-986142, a novel reversible BTK inhibitor, in healthy participants
por: Lee, Sun Ku, et al.
Publicado: (2017)

Acquired BTK mutations associated with resistance to noncovalent BTK inhibitors
por: Qi, Jialei, et al.
Publicado: (2023)

Pharmacokinetics of Oral Taurine in Healthy Volunteers
por: Ghandforoush-Sattari, Mohammadreza, et al.
Publicado: (2010)

Pharmacokinetics of chloroquine and primaquine in healthy volunteers
por: Daher, André, et al.
Publicado: (2022)

Pharmacokinetics of intranasal amiloride in healthy volunteers
por: Yellepeddi, Venkata K., et al.
Publicado: (2023)

Zanubrutinib for the treatment of lymphoid malignancies: Current status and future directions
por: Wolska-Washer, Anna, et al.
Publicado: (2023)

Pharmacokinetics of fluticasone furoate, umeclidinium, and vilanterol as a triple therapy in healthy volunteers
por: Brealey, Noushin, et al.
Publicado: (2015)

Effect of Probenecid on Pharmacokinetics and Tolerability of Olmesartan in Healthy Chinese Volunteers()
por: Li, Kun-Yan, et al.
Publicado: (2014)

Pooled safety analysis of zanubrutinib monotherapy in patients with B-cell malignancies
por: Tam, Constantine S., et al.
Publicado: (2022)

Effect of ketoconazole on the pharmacokinetics of axitinib in healthy volunteers
por: Pithavala, Yazdi K., et al.
Publicado: (2010)

Population pharmacokinetics of olprinone in healthy male volunteers
por: Kunisawa, Takayuki, et al.
Publicado: (2014)

Pharmacokinetics of oral and intravenous melatonin in healthy volunteers
por: Andersen, Lars P. H., et al.
Publicado: (2016)

Study of GABA in Healthy Volunteers: Pharmacokinetics and Pharmacodynamics
por: Li, Junfeng, et al.
Publicado: (2015)

Pharmacokinetics of Cromolyn and Ibuprofen in Healthy Elderly Volunteers
por: Brazier, David, et al.
Publicado: (2017)

Effect of Rifampicin on the Pharmacokinetics of Evogliptin in Healthy Volunteers
por: Shin, Yesong, et al.
Publicado: (2022)

Non-Covalent BTK Inhibitors—The New BTKids on the Block for B-Cell Malignancies
por: Lewis, Katharine L, et al.
Publicado: (2021)

BTK inhibitors in the treatment of hematological malignancies and inflammatory diseases: mechanisms and clinical studies
por: Alu, Aqu, et al.
Publicado: (2022)

Use of modeling and simulation to predict the influence of triazole antifungal agents on the pharmacokinetics of zanubrutinib and acalabrutinib
por: Chen, Lu, et al.
Publicado: (2022)

Application of a Novel ‘Make and Test in Parallel’ Strategy to Investigate the Effect of Formulation on the Pharmacokinetics of GDC-0810 in Healthy Subjects
por: Cheeti, Sravanthi, et al.
Publicado: (2018)

Differential impact of BTK active site inhibitors on the conformational state of full-length BTK
por: Joseph, Raji E, et al.
Publicado: (2020)

Cotargeting of BTK and MALT1 overcomes resistance to BTK inhibitors in mantle cell lymphoma
por: Jiang, Vivian Changying, et al.
Publicado: (2023)

Human Mass Balance and Metabolite Profiling of [(14)C]‐Pamiparib, a Poly (ADP‐Ribose) Polymerase Inhibitor, in Patients With Advanced Cancer
por: Mu, Song, et al.
Publicado: (2021)

Zanubrutinib: past, present, and future
por: Tam, Constantine S., et al.
Publicado: (2023)

A two‐part, single‐arm, multicentre, phase I study of zanubrutinib, a selective Bruton tyrosine kinase inhibitor, in Chinese patients with relapsed/refractory B‐cell malignancies
por: Song, Yuqin, et al.
Publicado: (2022)

Evaluation of the Effect of Food on the Pharmacokinetics of SHR6390, An Oral CDK4/6 Inhibitor, in Healthy Volunteers
por: Liu, Yan-ping, et al.
Publicado: (2022)

A Fast and Clean BTK Inhibitor
por: Gabizon, Ronen, et al.
Publicado: (2020)

Targeting Solid Tumors With BTK Inhibitors
por: Uckun, Fatih M., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_0frbnjd8lmqdd37udm59gqvrqi